• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract 249: Economic Outcomes for Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Receiving Prasugrel or Ticagrelor: A Retrospective US Hospital Database Analysis Session Title: Poster Session II
Conclusion: Economic outcomes of ACS-PCI pts receiving pras were similar to ticag for the primary population with significant savings in total and medical costs for pts without prior TIA or stroke. These data indicate that ticag has no economic advantage compared with pras in routine clinical practice.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Molife, C., Frech-Tamas, F., Effron, M. B., DeKoven, M., Karkare, S., Zhu, Y. E., Larmore, C., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Vetrovec, G. W. Tags: Session Title: Poster Session II Source Type: research

Abstract 257: A Long-Term Comparison of Clinical and Economic Outcomes with Novel Oral Anti- Coagulants Session Title: Poster Session II
Conclusions: While using NOACs in NVAF treatment raises drug costs compared to current practice, it also reduces stroke incidence. Among NOACs, apixaban does so at lower cost, with fewer bleeding events than either dabigatran or rivaroxaban.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Van Nuys, K., Kuznik, A., Phatak, H., Iloeje, U., Sullivan, J., Lakdawalla, D. N., Vasudeva, E., Weintraub, W. Tags: Session Title: Poster Session II Source Type: research

Abstract 261: Applying Clinical Trial Data to Real-World: Apixaban, Dabigatran, and Rivaroxaban Session Title: Poster Session II
CONCLUSIONS: If relative risk reductions from randomized clinical trials persist in the real-world, apixaban would result in the greatest clinical benefit versus warfarin of all NOACs in terms of stroke and major bleeding excluding intracranial hemorrhage events avoided.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Amin, A., Stokes, M., Wu, N., Gatt, E., Makenbaeva, D., Wiederkehr, D., Lawrence, J. H. Tags: Session Title: Poster Session II Source Type: research

Abstract 262: Aspirin vs. Warfarin Therapy Outcomes for Non-Valvular Atrial Fibrillation Patients with Moderate Stroke Risk Session Title: Poster Session II
Conclusion: ASA therapy was associated with a higher rate of stroke/SE but with a lower rate of bleed compared to TTR ≥55% warfarin in NVAF patients with CHADS2=1. These results suggest that treatment decisions should be carefully made based on the risk and benefit assessment in patients whose CHADS2=1.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: An, J., Jazdzewski, K. P., Le, P. T., Rashid, N., Lang, D. T., Niu, F., Meissner, B., Mendes, R., Dills, D., Bruno, A. Tags: Session Title: Poster Session II Source Type: research

Abstract 277: Conveying Risks and Benefits of rt-PA: the Eyes Have It Session Title: Poster Session II
Conclusions: Our preliminary data suggest that stacked bar graphs facilitate better understanding of the risks and benefits of rt-PA in acute IS. Presenting data in this format could better engage patients and families in making treatment decisions in the setting of IS.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Decker, C., Poirier, M. W., Chhatriwalla, E., Gialde, E., Spertus, J. A., Mayhugh, T. M., Schleicher, K. M., McDowd, J. M. Tags: Session Title: Poster Session II Source Type: research

Abstract 314: Impact of Spontaneous Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial Session Title: Poster Session III
CONCLUSION: Spontaneous bleeding events are associated with a negative impact on health state utility, with greatest immediate impact for major bleeds. Health state utility remains low 1 year after an ICH, but gradually returns to baseline 1-year after other major bleeding events. Future cost-effectiveness analysis of strategies to prevent stroke in AF should consider both the economic and health status impact of bleeding events to inform health care decision making.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Magnuson, E. A., Wang, K., Li, H., Kwong, W. J., Antman, E. M., Ruff, C. T., Murphy, S. A., Giugliano, R. P., Cohen, D. J. Tags: Session Title: Poster Session III Source Type: research

Abstract 320: Healthcare Resource Utilization Among Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Using Prasugrel or Ticagrelor: A Retrospective Database Analysis Session Title: Poster Session III
Conclusions: All-cause rehospitalizations at 30-and 90-days post discharge in ACS-PCI pts were non-inferior with pras vs. ticag in all 3 cohorts. Pras was associated with significantly lower risk for 90-day all-cause rehospitalizations compared with ticag in the label and core cohorts, which are the majority of pts receiving pras. Although there appears to be inherent bias and unmeasured confounders related to use of pras vs. ticag, these data show reductions in HCRU with pras compared with ticag in the real-world setting at 30- and 90-days post-discharge.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Molife, C., Effron, M. B., DeKoven, M., Karkare, S., Frech-Tamas, F., Larmore, C., Zhu, Y., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Vetrovec, G. W. Tags: Session Title: Poster Session III Source Type: research

Abstract 325: Paradoxical Relationship Between Bleeding Risk, Stroke Risk, and Time in Therapeutic Range for Atrial Fibrillation Patients on Warfarin: Data from ORBIT-AF Session Title: Poster Session III
Conclusions: In US clinical practices, warfarin patients have therapeutic INR levels about 2/3 of the time. Those at highest risk for stroke and bleeding paradoxically were the least likely to be in the therapeutic range.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Pokorney, S., Holmes, D. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Chang, P., Singer, D. E., Ansell, J., Blanco, R. G., Gersh, B., Mahaffey, K. W., Hylek, E. M., Go, A. S., Piccini, J. P., Peterson, E. D. Tags: Session Title: Poster Session III Source Type: research

Abstract 336: Real-World Experiences with Novel Anticoagulants for AF: Initial Insights from ORBIT-AF Phase II Session Title: Poster Session III
Conclusions: Patients with new-onset AF are frequently treated with novel anticoagulants and these patients have lower risk scores than those with known AF transitioned to a novel drug. These data will provide insights into clinical management and patient centered outcomes among those treated with novel anticoagulants in real world practice settings.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Steinberg, B. A., Milford-Beland, S., Ollis, D., Blanco, R., Ansell, J., Fonarow, G. C., Gersh, B., Go, A., Hylek, E., Kowey, P. R., Mahaffey, K. W., Thomas, L., Chang, P., Peterson, E. D., Piccini, J. P. Tags: Session Title: Poster Session III Source Type: research

Abstract 340: Thirty-day Repeat Hospitalizations for Patients Treated with Prasugrel Compared to Ticagrelor following Acute Coronary Syndrome: Findings from a Large Hospital Charge Master Database Session Title: Poster Session III
Conclusion: Rehosp for MI, revasc or bleeding was non-inferior for pras compared to ticag at 30 days post discharge. Pts treated with pras had lower 30 day rehosp rates, particularly related to readmission for MI, compared with ticag. Although limited by selection bias, these results support the clinical utility of pras, regardless of cohort, to limit 30 day rehosp for pts undergoing PCI for ACS.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Vetrovec, G. W., Larmore, C., Molife, C., DeKoven, M., Karkare, S., Zhu, Y. E., Frech-Tamas, F., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Effron, M. B. Tags: Session Title: Poster Session III Source Type: research

Abstract 141: Outcomes Associated with Temporarily Interrupting Anticoagulation in Outpatients with Atrial Fibrillation: Results from ORBIT-AF Session Title: Poster Session I
Conclusions: Temporary interruptions are common in patients receiving OAC for AF, however, bridging anticoagulation is used in a minority. Bleeding events following TI occurred significantly more often in patients receiving bridging anticoagulation.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Steinberg, B. A., Kim, S., Thomas, L., Sherwood, M. W., Gersh, B., Fonarow, G. C., Mahaffey, K. W., Kowey, P. R., Peterson, E. D., Piccini, J. P., Ansell, J. Tags: Session Title: Poster Session I Source Type: research

Abstract 169: The Role Of Clinical Prediction Factors On Anticoagulant Selection In Atrial Fibrillation Session Title: Poster Session I
Conclusions: Despite controlling for other patient characteristics, bleeding risk was strongly associated with the selection of a specific anticoagulant. However, the extent of selection explained by predictions of treatment harm was minimal. Providers appear to base anticoagulant selection on factors other than predictions of treatment benefit, which has implications for studying the anticoagulants’ comparative effectiveness.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Lauffenburger, J. Tags: Session Title: Poster Session I Source Type: research

Abstract 232: Comparison of Different Management Strategies for Acute Myocardial Infarction: A Multivariable Network Meta-analysis Session Title: Poster Session II
Conclusions: Primary PCI is the preferred approach for treatment of STEMI. Our analysis suggests that a pharmacoinvasive approach may be more effective and safer as compared to facilitated PCI and thrombolytic therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Fazel, R., Nallamothu, B. K. Tags: Session Title: Poster Session II Source Type: research

Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Original Articles
Conclusions— In community-based outpatients with AF, use of OAC was high and driven by not only predominantly stroke but also bleeding risk. Stroke risk significantly affects OAC use among those with low bleeding risk, whereas those with high bleeding risk demonstrate consistently lower use of OAC regardless of stroke risk.
Source: Circulation: Cardiovascular Quality and Outcomes - July 16, 2013 Category: Cardiology Authors: Cullen, M. W., Kim, S., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., Singer, D. E., Mahaffey, K. W., Kowey, P. R., Thomas, L., Go, A. S., Lopes, R. D., Chang, P., Peterson, E. D., Gersh, B. J., on behalf of the ORBIT-AF Investigators Tags: Coumarins, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Risk Factors for Stroke, Anticoagulants Original Articles Source Type: research

Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Concurrent I Session B: Oral Abstract Presentations on Stroke Topics
Conclusions. Contraindications to OAC therapy among AF patients are common and often due to high bleeding risk. Furthermore, many patients with reported contraindications are taking warfarin, suggesting that many contraindications to warfarin therapy are minor, relative, or temporary.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: O'Brien, E. C., Holmes, D., Koller, C. R., Singer, D. E., Ansell, J., Allen, L. A., Hylek, E. M., Kowey, P., Gersh, B., Fonarow, G. C., Mahaffey, K. W., Chang, P., Ezekowitz, M. D., Peterson, E. D., Piccini, J. P. Tags: Concurrent I Session B: Oral Abstract Presentations on Stroke Topics Source Type: research

Pages: 1  2  3  4  5